These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36471413)

  • 1. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial.
    Willemse SW; Roes KCB; Van Damme P; Hardiman O; Ingre C; Povedano M; Wray NR; Gijzen M; de Pagter MS; Demaegd KC; Janse AFC; Vink RG; Sleutjes BTHM; Chiò A; Corcia P; Reviers E; Al-Chalabi A; Kiernan MC; van den Berg LH; van Es MA; van Eijk RPA
    Trials; 2022 Dec; 23(1):978. PubMed ID: 36471413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
    ; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T
    Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis.
    Yang B; Jiang H; Wang F; Li S; Wu C; Bao J; Zhu Y; Xu Z; Liu B; Ren H; Yang X
    Neurol Sci; 2019 Nov; 40(11):2293-2302. PubMed ID: 31201598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.
    van Eijk RPA; Jones AR; Sproviero W; Shatunov A; Shaw PJ; Leigh PN; Young CA; Shaw CE; Mora G; Mandrioli J; Borghero G; Volanti P; Diekstra FP; van Rheenen W; Verstraete E; Eijkemans MJC; Veldink JH; Chio A; Al-Chalabi A; van den Berg LH; van Es MA;
    Neurology; 2017 Oct; 89(18):1915-1922. PubMed ID: 28978660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.
    Verstraete E; Veldink JH; Huisman MH; Draak T; Uijtendaal EV; van der Kooi AJ; Schelhaas HJ; de Visser M; van der Tweel I; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):557-64. PubMed ID: 22378918
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Willemse SW; Harley P; van Eijk RPA; Demaegd KC; Zelina P; Pasterkamp RJ; van Damme P; Ingre C; van Rheenen W; Veldink JH; Kiernan MC; Al-Chalabi A; van den Berg LH; Fratta P; van Es MA
    J Neurol Neurosurg Psychiatry; 2023 Aug; 94(8):649-656. PubMed ID: 36737245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis.
    Tan HHG; Westeneng HJ; van der Burgh HK; van Es MA; Bakker LA; van Veenhuijzen K; van Eijk KR; van Eijk RPA; Veldink JH; van den Berg LH
    Ann Neurol; 2020 Oct; 88(4):796-806. PubMed ID: 32627229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial.
    Chiò A; Borghero G; Calvo A; Capasso M; Caponnetto C; Corbo M; Giannini F; Logroscino G; Mandrioli J; Marcello N; Mazzini L; Moglia C; Monsurrò MR; Mora G; Patti F; Perini M; Pietrini V; Pisano F; Pupillo E; Sabatelli M; Salvi F; Silani V; Simone IL; Sorarù G; Tola MR; Volanti P; Beghi E;
    Neurology; 2010 Aug; 75(7):619-25. PubMed ID: 20702794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the risk factor
    Manini A; Casiraghi V; Brusati A; Maranzano A; Gentile F; Colombo E; Bonetti R; Peverelli S; Invernizzi S; Gentilini D; Messina S; Verde F; Poletti B; Fogh I; Morelli C; Silani V; Ratti A; Ticozzi N
    Front Aging Neurosci; 2023; 15():1067954. PubMed ID: 36819716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort.
    Vidal-Taboada JM; Lopez-Lopez A; Salvado M; Lorenzo L; Garcia C; Mahy N; Rodríguez MJ; Gamez J
    J Neurol; 2015 Oct; 262(10):2285-92. PubMed ID: 26162714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
    Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
    Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.
    Miller RG; Moore DH; Forshew DA; Katz JS; Barohn RJ; Valan M; Bromberg MB; Goslin KL; Graves MC; McCluskey LF; McVey AL; Mozaffar T; Florence JM; Pestronk A; Ross M; Simpson EP; Appel SH;
    Neurology; 2011 Sep; 77(10):973-9. PubMed ID: 21813790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis.
    Placek K; Baer GM; Elman L; McCluskey L; Hennessy L; Ferraro PM; Lee EB; Lee VMY; Trojanowski JQ; Van Deerlin VM; Grossman M; Irwin DJ; McMillan CT
    Neurobiol Aging; 2019 Jan; 73():190-199. PubMed ID: 30368160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UNC13A is a modifier of survival in amyotrophic lateral sclerosis.
    Diekstra FP; van Vught PW; van Rheenen W; Koppers M; Pasterkamp RJ; van Es MA; Schelhaas HJ; de Visser M; Robberecht W; Van Damme P; Andersen PM; van den Berg LH; Veldink JH
    Neurobiol Aging; 2012 Mar; 33(3):630.e3-8. PubMed ID: 22118904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.